Pill may keep leukemia at bay: new trial tests oral azacitidine as maintenance therapy

NCT ID NCT05413018

Ongoing Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether an oral chemotherapy drug called azacitidine (CC-486) can help prevent acute myeloid leukemia from coming back in Chinese patients who are already in complete remission after initial treatment. About 34 participants will receive either the drug or a placebo, along with best supportive care. The study aims to see if the drug extends the time before relapse and improves overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

oral azacitidine (CC-486, Onureg)

What this could lead to

If successful, this could provide a convenient oral maintenance option to help keep acute myeloid leukemia in remission longer for Chinese patients.

What could go wrong

This is a small, early-phase (phase 2) study with only 34 participants, so results may not apply broadly. The drug may cause side effects and might not improve survival or prevent relapse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, MYELOID, ACUTE

Contacts and locations

Show contact details

Locations

Local Institution - 0001

Tianjin, TJ, 300020, China
Local Institution - 0002

Shijiazhuang, HE, 050000, China
Local Institution - 0003

Guangzhou, GD, 510080, China
Local Institution - 0004

Zhengzhou, 450008, China
Local Institution - 0005

Shenyang, Liaoning, 110001, China
Local Institution - 0006

Shanghai, SH, 200025, China
Local Institution - 0007

Wenzhou, ZJ, 325015, China
Local Institution - 0008

Guangzhou, GD, 510080, China
Local Institution - 0009

Ürümqi, Xinjiang, 830011, China
Local Institution - 0010

Shenzhen, GD, 518055, China
Local Institution - 0011

Jinan, 250012, China
Local Institution - 0012

Guangzhou, 510060, China
Local Institution - 0013

Beijing, BJ, 100044, China
Local Institution - 0014

Hangzhou, 310009, China
Local Institution - 0015

Changsha, 410013, China
Local Institution - 0016

Chengdu, SC, 610041, China
Local Institution - 0017

Changchun, 130021, China
Local Institution - 0018

Nanchang, 330006, China
Local Institution - 0019

Changsha, 410008, China
Local Institution - 0020

Shenyang, LN, 110022, China
Local Institution - 0021

Suzhou, 215006, China
Local Institution - 0022

Xuzhou, Jiangsu, 221000, China
Local Institution - 0023

Tianjin, 300052, China
Local Institution - 0024

Kunming, 650032, China
Local Institution - 0026

Lanzhou, 730030, China
Local Institution - 0027

Beijing, BJ, 100191, China
Local Institution - 0028

Chongqing, CQ, 400000, China
Local Institution - 0029

Nanjing, 210029, China
Local Institution - 0030

Xi'an, SN, 710100, China
Local Institution - 0031

Hefei, Anhui, 230001, China
Local Institution - 0032

Harbin, 150086, China
Local Institution - 0033

Taiyuan, SX, 030013, China
Local Institution - 0034

Zhangzhou, 363000, China
Local Institution - 0035

Ganzhou, 341000, China